Catatonia Related to Cannabis and Synthetic Cannabinoids: A Review

Palma-Álvarez, Raúl Felipe; Soriano-Día, Albert; Ros-Cucurull, Elena; Daigre, Constanza; Serrano-Pérez, Pedro; Ortega-Hernández, Germán; Perea-Ortueta, Marta; Salas, David Gurrea; Ramos-Quiroga, Josep-Antoni; Grau-López, Lara

doi:10.1080/15504263.2021.1904163

Cited by 10 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although cannabis-induced catatonia is a severe and potentially life-threatening condition, considering its widespread use and its legalization for medical purposes in numerous clinical settings, the existing literature on this condition remains incomplete and inconsistent. A recent comprehensive systematic review, spanning 19 years up to 2020, revealed 14 published cases across 11 studies that establish a relationship between catatonia and cannabis or synthetic cannabinoids (SCs) (4). Furthermore, a cross-sectional study conducted by Yeoh et al (5) examined electronic health records in London.…”

Section: Literature Reviewmentioning

confidence: 99%

“…Cannabis-induced catatonia constitutes a rare yet potentially grave condition in which the utilization of cannabis, colloquially known as marijuana, becomes associated with the manifestation of catatonic symptoms (4). While, generally, cannabis is deemed to carry a lower risk of inducing catatonia when juxtaposed with other substances such as stimulants or hallucinogens (5), instances have been documented where the use of cannabis coincided with the emergence of catatonic symptoms.…”

Section: Introductionmentioning

confidence: 99%

“…Tetrahydrocannabinol (THC), a constituent of cannabis, exerts an impact on the endocannabinoid system, potentially disrupting the regulatory functions of GABA and glutamate (8). Certain cases have established a link between cannabis use and catatonia, particularly in instances of heightened potency and frequency of use (4). Substantial research is warranted concerning cannabis-induced catatonia, with a specific focus on comprehending its risk factors and treatment modalities.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Recurrent cannabis-induced catatonia: a case report and comprehensive systematic literature review

Moshfeghinia,

Hosseinzadeh,

Mostafavi

et al. 2024

Front. Psychiatry

View full text Add to dashboard Cite

BackgroundCatatonia presents itself as a complex neuropsychiatric syndrome, giving rise to various motor, speech, and behavioral challenges. It is noteworthy that approximately 10% of psychiatric hospital admissions can be attributed to this condition. It is imperative to note that cannabis-induced catatonia, while infrequent, has been linked to the use of marijuana. This connection has the potential to disrupt neurotransmitter systems, necessitating further research for a comprehensive understanding and effective treatment, particularly given the evolving trends in cannabis use. In this context, we shall delve into a unique case of recurrent cannabis-induced catatonia.Case presentationA 23-year-old gentleman, who has previously struggled with substance use disorder, experienced the emergence of mutism, social isolation, and a fixed gaze subsequent to his use of cannabis. Remarkably, despite the absence of hallucinations, he exhibited recurrent episodes of catatonia. These episodes were effectively addressed through a combination of electroconvulsive therapy (ECT) and lorazepam administration. Notably, when the lorazepam dosage was gradually reduced to below 2 mg per day, the catatonic symptoms resurfaced; however, they promptly abated upon reinstating the medication. The diagnosis of cannabis-induced catatonia was established, and its management primarily involved a therapeutic approach encompassing ECT and lorazepam. It is pertinent to underscore that this catatonic condition can be directly linked to the individual’s cannabis usage.ConclusionThe connection between cannabis and catatonia is intricate and not entirely comprehended. Although cannabis possesses therapeutic advantages, it can paradoxically trigger catatonia in certain individuals. Multiple factors, such as genetics, cannabinoids, and neurotransmitter systems, contribute to this intricacy, underscoring the necessity for additional research.

show abstract

Section: Literature Reviewmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Recurrent cannabis-induced catatonia: a case report and comprehensive systematic literature review

Moshfeghinia,

Hosseinzadeh,

Mostafavi

et al. 2024

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…U 10 osób, zastosowano leki antypsychotyczne głównie II generacji. Wśród stosowanych alternatywnych metod leczenia (nigdy jako monoterapia) wymieniono: difenhydraminę, kwas walproinowy, duloksetynę, sertralinę, biperyden i terapię elektrowstrząsowa [39].…”

Section: Covid-19unclassified

On catatonia again... - literature review

RUDZINSKI

Brzuszkiewicz

Pożarowska

et al. 2023

J Educ Health Sport

View full text Add to dashboard Cite

Introduction: In addition to the symptoms, the symptoms of catatonia have been classified as a subtype of schizophrenia (catatonic schizophrenia). Currently, however, catatonia is treated as a single psychopathological syndrome that can occur in the course of various disorders. Catatonia has been the subject of many disputes in the scientific community over the years, and many of its elements remain unexplored. Material and method: The aim of the study is to review current research on catatonia in the field of: main, leading to catatonia, neuroimaging, immunology, methods of treatment and psychoactive compounds, COVID-19, therapy of pediatric and geriatric patients. The article reviews research and scientific papers from 2014-2022 on catatonia, interest in the PubMed and Google Scholar databases. Results: Studies showing a prevalence of catatonia of approximately 10.6 cases per 100,000 tax recipients. The assessment of the prevalence of individual catatonias varies depending on the criteria. Deep vein embolism has been confirmed in approximately 25.3% of patients with cardiac catatonia. Conclusions: Catatonia is a common neuropsychiatric syndrome that significantly prolongs hospitalization time. Additional studies using the technique of functional neuroimaging of the brain are needed. Effects of treatment with the effect of: zolpidem, memantine, amantadine and augmentation with amisulpiride.

show abstract